Navigation Links
Doctor Grilled In Court For False Report About Vioxx Health Risk

The doctor, who had dismissed increased risk of heart attack associated with Vioxx, has been accused by lawyers who argue that his views are 'out of the mainstream' as it is based on biased research //, funded by the drug company, Merck and Co.

Thomas Cona and John Mcdarby have sued the pharmaceutical company, stating that use of the drug had resulted in heart attacks. More than 10, 000 different lawsuits has been filed against the controversial Vioxx, on grounds of product liability. The product, originally intended for arthritis treatment was withdrawn from the market in the September of 2004.

The case was taken up for hearing recently. Attorney Mark Lanier questioned the motivation and educational qualifications of Merck expert witness Dr. Barry Rayburn during the cross-examination. He works as a cardiologist in the University of Alabama. He further stated that anyone who had not taken money from Merck would deserve to be called mainstream doctor.

The attorney who stands for Thomas Cona is the only who had won a case against Merck, last August. He enabled a Texas based widow, a user of Vioxx receive a multimillion-dollar jury award. Other similar trials that were taken up in the state and federal courts had ended up in favor of Merck.

Rayburn was peppered with questions about studies and articles that demonstrated an increased risk of heart attack in those who used Vioxx. This however was not included in the doctor’s testimony that was submitted in the court on Tuesday. To this Rayburn responded by saying that some of the articles or studies cited by Lanier were not included in his testimony because he 'felt it was important to look at things that were peer reviewed. I also looked at many studies we have not talked about'.

The close scrutiny by several other experts in a specific field confers the peer-reviewed studies, a higher credibility. Every attempt is made to ensure that the study was indeed desig ned and conducted in a systematic way, to meet the industry standards. The cardiologist pointed out to the study conducted on more than 28, 000 patients that had no evidence of increased heart attack or other cardiovascular complications.

In addition, Rob Gordon, a lawyer representing McDarby, grilled Rayburn about his legal work for Merck, his payment and involvement in other clinical trials conducted by the drug company.

Following a study, which showed for the first time that use of the drug for a period of 18 months, doubled the heart attack risk; the pain relief was withdrawn from the drug market.

The conclusion, according to the lawyers is that although it was known that the drug increased risk of heart attacks in users, the drug company failed to warn the users, compromising on patient safety for want of profit.


Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Doctors needed urgently in Gujarat
3. Doctors operate upon patients in candlelight- latest from the quake scene
4. Doctors at risk- the ugly side of the noble profession
5. Doctors advice early anemia tests
6. Indian Doctor granted US patent on organ regeneration
7. Emphasis to ban Drugs ads by Doctors
8. Doctor samples come under the ambit of advertisement
9. Doctors not to accept gifts from drug companies
10. Gene testing kit specific for Doctors
11. Doctors warned of fluoride toxicity
Post Your Comments:

(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
(Date:11/30/2015)... ... 30, 2015 , ... The presidential race normally deals with political issues of ... a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? ... than anyone wants to admit when it comes to how people are viewed by ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one ... , Their study showed that small molecule analogs that target the functions of ...
(Date:11/30/2015)... ... 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics and is ... Margulies to experience the best available orthodontic experience in the area. Dr. Margulies ... , Orthodontics is the branch of dentistry that specializes in the diagnosis, prevention, and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
Breaking Medicine Technology: